Abstract
This retrospective chart review examines the safety, tolerability and effectiveness of long acting injectable paliperidone palmitate (P-LAI) targeting irritability in twenty-six youth and transition-aged individuals with autism spectrum disorder (ASD) and/or intellectual disability (ID) over a 3-year window. Clinical response was evaluated via prospectively assigned Clinical Global Impressions Severity (CGI-S) and Improvement (CGI-I) scales as well as number of hospital presentations. P-LAI was well tolerated with only 3 patients stopping P-LAI due to side effects. The average duration of P-LAI treatment was 21.1 months. Difficulty with medication compliance was the most common reason for initiating P-LAI. There was a statistically significant improvement in CGI-I, CGI-S and hospital visits and no change in BMI noted. Given the potential difficulty of medication administration in this population, this evidence of safety, tolerability as well as preliminary data supporting effectiveness is an important addition to the literature regarding psychopharmacologic management of irritability in youth with ASD and ID.
This is a preview of subscription content, log in via an institution to check access.
References
Aman, M. G., Singh, N. N., Stewart, A. W., & Field, C. J. (1985). The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency, 89(5), 485–491.
Blankenship, K., Erickson, C. A., Stigler, K. A., Posey, D. J., & McDougle, C. J. (2010). Aripiprazole for irritability associated with autistic disorder in children and adolescents aged 6–17 years. Pediatric Health, 4(4), 375–381. https://doi.org/10.2217/phe.10.45
Cohen, D., Raffin, M., Canitano, R., Bodeau, N., Bonnot, O., Périsse, D., Consoli, A., & Laurent, C. (2013). Risperidone or aripiprazole in children and adolescents with autism and/or intellectual disability: A Bayesian meta-analysis of efficacy and secondary effects. Research in Autism Spectrum Disorder, 7(1), 167–175.
Fortea, A., Ilzarbe, D., Espinosa, L., Solerdelcoll, M., de Castro, C., Oriolo, G., Sugranyes, G., & Baeza, I. (2018). Long-acting injectable atypical antipsychotic use in adolescents: An observational study. Journal of Child and Adolescent Psychopharmacology, 28(4), 252–257. https://doi.org/10.1089/cap.2017.0096
Gopal, S., Xu, H., Bossie, C., Burón, J. A., Fu, D. J., Savitz, A., Nuamah, I., & Hough, D. (2014). Incidence of tardive dyskinesia: a comparison of long-acting injectable and oral paliperidone clinical trial databases. International Journal of Clinical Practice, 68(12), 1514–1522. https://doi.org/10.1111/ijcp.12493
Guy, W., National Institute of Mental, H., Psychopharmacology Research, B., & Early Clinical Drug Evaluation, P. (1976). ECDEU assessment manual for psychopharmacology. US Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs.
Institute, C. s. H. o. P. R. (2021). Pediatric Z‐Score Calculator. Retrieved August 10, 2021, from https://zscore.research.chop.edu/calcbmi.php
Kowalski, J. L., Wink, L. K., Blankenship, K., Habenicht, C. D., Erickson, C. A., Stigler, K. A., & McDougle, C. J. (2011). Paliperidone palmitate in a child with autistic disorder. Journal of Child and Adolescent Psychopharmacology, 21(5), 491–493. https://doi.org/10.1089/cap.2011.0035
Leung, J. G., Kooda, K. J., Frazee, E. N., Nelson, S., & Moore, K. M. (2015). Paliperidone palmitate associated with necrotizing deep tissue infection and sepsis requiring surgical intervention. Case Rep Psychiatry, 2015, 364325. https://doi.org/10.1155/2015/364325
Lytle, S., McVoy, M., & Sajatovic, M. (2017). Long-acting injectable antipsychotics in children and adolescents. Journal of Child and Adolescent Psychopharmacology, 27(1), 2–9. https://doi.org/10.1089/cap.2016.0055
Maneeton, N., Maneeton, B., Putthisri, S., Suttajit, S., Likhitsathian, S., & Srisurapanont, M. (2018a). Aripiprazole in acute treatment of children and adolescents with autism spectrum disorder: A systematic review and meta-analysis. Neuropsychiatric Disease and Treatment, 14, 3063–3072. https://doi.org/10.2147/NDT.S174622
Maneeton, N., Maneeton, B., Putthisri, S., Woottiluk, P., Narkpongphun, A., & Srisurapanont, M. (2018b). Risperidone for children and adolescents with autism spectrum disorder: A systematic review. Neuropsychiatric Disease and Treatment, 14, 1811–1820. https://doi.org/10.2147/NDT.S151802
Mazefsky, C. A., Day, T. N., Siegel, M., White, S. W., Lan, Y., Pilkonis, P. A., & Autism and Developmental Disabilities Inpatient Research Collaborative (ADDIRC). (2018). Development of the emotion dysregulation inventory: A PROMIS® ing method for creating sensitive and unbiased questionnaires for autism spectrum disorder. Journal of Autism and Developmental Disorders, 48(11), 3736–3746.
McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., McDougle, C. J., Posey, D., Swiezy, N., Kohn, A., Scahill, L., Martin, A., Koenig, K., Volkmar, F., Carroll, D., … Research Units on Pediatric Psychopharmacology Autism, N. (2002). Risperidone in children with autism and serious behavioral problems. New England Journal of Medicine, 347(5), 314–321. https://doi.org/10.1056/NEJMoa013171
McDougle, C. J., Scahill, L., Aman, M. G., McCracken, J. T., Tierney, E., Davies, M., Arnold, L. E., Posey, D. J., Martin, A., Ghuman, J. K., Shah, B., Chuang, S. Z., Swiezy, N. B., Gonzalez, N. M., Hollway, J., Koenig, K., McGough, J. J., Ritz, L., & Vitiello, B. (2005). Risperidone for the core symptom domains of autism: Results from the study by the autism network of the research units on pediatric psychopharmacology. American Journal of Psychiatry, 162(6), 1142–1148. https://doi.org/10.1176/appi.ajp.162.6.1142
Misawa, F., Kishimoto, T., Hagi, K., Kane, J. M., & Correll, C. U. (2016). Safety and tolerability of long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled studies comparing the same antipsychotics. Schizophrenia Research, 176(2), 220–230.
Stigler, K. A., Erickson, C. A., Mullett, J. E., Posey, D. J., & McDougle, C. J. (2010). Paliperidone for irritability in autistic disorder. Journal of Child and Adolescent Psychopharmacology, 20(1), 75–78. https://doi.org/10.1089/cap.2009.0019
Stigler, K. A., Mullett, J. E., Erickson, C. A., Posey, D. J., & McDougle, C. J. (2012). Paliperidone for irritability in adolescents and young adults with autistic disorder. Psychopharmacology (berl), 223(2), 237–245. https://doi.org/10.1007/s00213-012-2711-3
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors have no disclosures related to this manuscript.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Simpson, S., Dominick, K.C., Erickson, C.A. et al. Safety and Efficacy of Paliperidone Palmitate in Pediatric Patients with Autism and Intellectual Disability. J Autism Dev Disord (2024). https://doi.org/10.1007/s10803-024-06372-9
Accepted:
Published:
DOI: https://doi.org/10.1007/s10803-024-06372-9